Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Drug Nomenclature

Drug Nomenclature

During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that the same...

Drug Classes and Categories

Drug Classes and Categories

Drugs can be classified according to their chemical composition or their intended therapeutic application. For instance, anti-infective agents that possess the ability to eliminate pathogens or suppress their growth and reproduction can be grouped based on the organisms they target or their chemical structure. Furthermore, drugs can be divided into prescription, nonprescription, or controlled substances. Prescription medications, such as antibiotics, require oversight from a licensed healthcare...

Prescription, Nonprescription and Orphan Drugs

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Year's New Drugs & Biologics - 2009.

Drug news & perspectives·2010

Same author

Overcoming the obstacles in the pharma/biotech industry: 2009 update.

Drug news & perspectives·2010

Same author

The year's new drugs & biologics - 2008.

Drug news & perspectives·2009

Same author

Promoting, improving and accelerating the drug development and approval processes.

Drug news & perspectives·2009

Same author

Overcoming the obstacles in the pharma/biotech industry: 2008 update.

Drug news & perspectives·2009

Same author

The year's new drugs.

Drug news & perspectives·2006

Search research articles

Related Experiment Video

Updated: Jul 17, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

The year's new drugs.

¹Prous Science, Barcelona, Spain. agraul@prous.com

Drug News & Perspectives

|March 3, 2004

Summary

In 2003, 30 new molecular entities and biologic drugs and two diagnostic agents were launched globally. The Endocrine and Metabolic Drugs therapeutic group led new product introductions, with the United States as the primary market.

Area of Science:

Pharmacology and Therapeutics
Drug Discovery and Development
Health Economics and Outcomes Research

Background:

This annual review tracks new molecular entities and biologic drugs launched globally.
The article provides a historical and research-based perspective on recent pharmaceutical innovations.
It serves as a benchmark for drug development and market access trends.

Purpose of the Study:

To document and analyze new molecular entities and biologic drugs first marketed in 2003.
To identify key therapeutic areas and geographical markets for new drug launches.
To provide insights into the landscape of pharmaceutical innovation and market penetration.

Main Methods:

Data collection on new drug approvals and market launches worldwide for 2003.

More Related Videos

Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones

Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones

Published on: February 5, 2018

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Related Experiment Videos

Last Updated: Jul 17, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones

Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones

Published on: February 5, 2018

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Categorization of new products by therapeutic class and country of first market introduction.

Analysis of market dynamics and trends based on launch data.

Main Results:

30 new chemical entities and biologic drugs, plus two diagnostic agents, reached their first markets in 2003.
An additional six products were approved in 2003 but launched subsequently.
Endocrine and Metabolic Drugs was the leading therapeutic group with six new launches.
The United States led in new product launches, accounting for 20 introductions (66.6% of total).

Conclusions:

The year 2003 saw significant activity in new drug development and market entry.
The Endocrine and Metabolic therapeutic area was a key focus for pharmaceutical companies.
The United States remains a dominant market for the launch of novel therapeutics.